Accelerating Innovation, Commercialization and Globalization In the first half of 2025, InnoCare made substantial progress in advancing its pipeline with multiple key milestones achieved: Orelabrutinib received approval for first-line chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), tafasitamab in combination with lenalidomide was approved for adult patients with relapsed or refractory DLBCL (R/R DLBCL), BCL-2 inhibitor Mesutoclax (ICP-248) entered two registrational clinical studies, the NDA for TRK inhibitor Zurletrectinib (ICP-723) was accepted and granted priority review, and the Company's proprietary antibody-drug conjugate (ADC) platform reached a major milestone with IND approval. Building on this R&D momentum, InnoCare further expanded its global footprint through strategic collaborations. In January, InnoCare partnered with Prolium to explore global potential for a CD3×CD20 bispecific antibody.